BioCardia, Inc. (BCDA)
Company Description
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.
Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease.
The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure.
In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths.
The company is based in Sunnyvale, California.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Peter Altman |
Contact Details
Address:
125 Shoreway Road, Suite B San Carlos, California 94070 United States | |
| Phone | 650-226-0123 |
| Website | biocardia.com |
Stock Details
| Ticker Symbol | BCDA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000925741 |
| CUSIP Number | 09060U507 |
| ISIN Number | US09060U5074 |
| Employer ID | 23-2753988 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter A. Altman Ph.D. | Chief Executive Officer, President and Director |
| David McClung | Chief Financial Officer |
| Edward M. Gillis | Senior Vice President of Devices |
| Dr. Ian McNiece Ph.D. | Chief Scientific Officer |
| Dr. Sujith Shetty | Chief Medical Officer and Vice President of Clinical and Regulatory |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2023 | 8-K | Current Report |
| Feb 13, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 1, 2023 | 8-K | Current Report |
| Jan 9, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jan 9, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 28, 2022 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 22, 2022 | EFFECT | Notice of Effectiveness |
| Dec 22, 2022 | 8-K | Current Report |
| Dec 19, 2022 | S-3 | Registration statement under Securities Act of 1933 |
| Dec 15, 2022 | 8-K | Current Report |